These findings suggest that reduced cytotoxic T-cell infiltration is associated with adverse clinical outcomes, positioning CD8+ T cells as a potentially protective immune component in ABC DLBCL. The gene discussed is CD8A; the disease is diffuse large B-cell lymphoma.